MEK inhibitor

In today's episode, we spoke with Vincent Chung, MD, about the development of atebometinib in metastatic pancreatic cancer.

In our exclusive interview, Dr. Chung discussed MEK inhibition as a logical target in metastatic pancreatic cancer, the unique mechanism of action of atebometinib that contributes to its improved tolerability relative to earlier generation MEK inhibitors, key safety and efficacy findings from a Phase IIa trial combining atibimetinib with modified gemcitabine nabpaclitaxel in patients with advanced stromatostatic disease, and how the outcomes of the ongoing Phase III MapKeeper 301 trial may affect the treatment paradigm going forward.

Thank you so much, Dr. Chung, for taking the time to speak with us today on an episode of OncLive OnAir.

Just to start off, what is the mechanism of action of atibimetinib and what is the rationale for combining this agent with gemcitabine and nabpaclitaxel in pancreatic cancer?